<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02334579</url>
  </required_header>
  <id_info>
    <org_study_id>IR 5642</org_study_id>
    <nct_id>NCT02334579</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer</brief_title>
  <official_title>Function-Preserving Stereotactic Body Radiotherapy for Clinical State I-III Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the effects (good and bad) of highly focused
      radiation on you and your prostate cancer. The purpose of this evaluation is to see if this
      treatment causes fewer side effects that other standard treatment approaches, and to evaluate
      the effect of this treatment on your prostate tumor and your quality of life over time.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life outcomes (low- and intermediate-risk prostate cancer groups)</measure>
    <time_frame>8 years</time_frame>
    <description>In the low- and intermediate-risk prostate cancer groups, to determine whether study treatment improves patient-reported quality of life outcomes compared to the approach used in a previous multi-center cyberknife stereotactic radiosurgery trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of acute and late grade 3-5 gastrointestinal and genitourinary toxicities (high-risk group)</measure>
    <time_frame>8 years</time_frame>
    <description>In the high-risk group, to estimate rates of acute and late grade 3-5 gastrointestinal and genitourinary toxicities following cyberknife stereotactic radiosurgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of toxicities related to treatment</measure>
    <time_frame>5 years</time_frame>
    <description>After five years following cyberknife stereotactic radiosurgery, estimate rates of toxicities related to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Measure disease free survival after five years following cyberknife stereotactic radiosurgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Measure overall survival after five years following cyberknife stereotactic radiosurgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Measure quality of life after five years following cyberknife stereotactic radiosurgery.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Cancer</condition>
  <condition>Prostate Neoplasms</condition>
  <condition>Prostatic Neoplasms</condition>
  <condition>Cancer of the Prostate</condition>
  <arm_group>
    <arm_group_label>CyberKnife Stereotactic Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife Stereotactic Radiosurgery</intervention_name>
    <description>Five treatments given over about one week.</description>
    <arm_group_label>CyberKnife Stereotactic Radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven prostate adenocarcinoma

          -  Clinical stage T1a-T3, N0-Nx, M0-Mx

          -  Patients belonging in one of the following risk groups: (1) LOW RISK: CS T1a-T2a,
             Gleason 2-6, PSA&lt;10, Nx-0, Mx-0; (2) INTERMEDIATE RISK: CS T2b, Gleason ≤7, PSA&lt;20,
             Nx-0, Mx-0, or CS T1a-T2b, Gleason 2-6, PSA≥10 &amp; &lt;20, Nx-0, Mx-0, or CS T1a-T2b,
             Gleason 7, PSA≤20, Nx-0, Mx-0; or (3) HIGH RISK: CS T2c-T3, any Gleason, any PSA, or
             CS T1-3, Gleason ≥8 and/or PSA≥20

          -  Karnofsky performance status 70-100

          -  Hormone therapy: includes LHRH agonists (e.g. leuprolide, goserelin, triptorelin),
             antagonists (e.g. degarelix), peripheral blockers (e.g. flutamide, bicalutamide,
             nilutamide), estrogens (e.g. DES) and bilateral orchiectomy

          -  Low and Intermediate risk groups: no hormone ablation for two months prior to
             enrollment, or during treatment

          -  High risk group: three hormone therapy regimens are allowed

          -  5-alpha reductase inhibitors (e.g., finasteride or dutasteride) are allowed

        Exclusion Criteria:

          -  Prior prostatectomy or cryotherapy of the prostate

          -  Prior high-dose radiotherapy to the prostate or lower pelvis

          -  Implanted hardware or other material that would prohibit appropriate treatment
             planning or treatment delivery, in the investigator's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Meier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center Radiosurgery Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Monahan</last_name>
    <phone>(206) 320-7129</phone>
    <email>mary.monahan@swedish.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Meier, MD</last_name>
    <phone>(206) 320-7130</phone>
    <email>robert.meier@swedish.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swedish Medical Center Radiosurgery Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Monahan</last_name>
      <phone>206-320-7029</phone>
      <email>mary.monahan@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Robert Meier, MD</last_name>
      <phone>(206) 320-7130</phone>
      <email>robert.meier@swedish.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Meier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.swedish.org/services/radiosurgery-center</url>
    <description>Swedish Medical Center Radiosurgery Center</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2015</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiation</keyword>
  <keyword>Stereotactic Radiosurgery</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Prostate Tumor</keyword>
  <keyword>Prostate Surgery</keyword>
  <keyword>CyberKnife</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

